Anzeige
Mehr »
Login
Samstag, 19.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Trumps Dekret beschleunigt Antimon-Boom - Wird Global Tactical der nächste Highflyer für kritische Mineralien?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D4A6 | ISIN: US1717572069 | Ticker-Symbol: 20D0
Frankfurt
17.04.25
09:17 Uhr
16,600 Euro
-0,500
-2,92 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CIDARA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CIDARA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
16,70017,40017.04.
16,70017,40017.04.

Aktuelle News zur CIDARA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiCantor Fitzgerald maintains Overweight on Cidara Therapeutics stock2
01.04.Cidara Therapeutics, Inc.: Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)70SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak®?platform to develop drug-Fc conjugate (DFC) immunotherapies...
► Artikel lesen
17.03.Cidara Therapeutics Publishes Preclinical Data On CD388 In Nature Microbiology2
17.03.Cidara Therapeutics, Inc.: Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology3
12.03.Citizens initiates Cidara with Market Outperform on inlfuenza prevention opportunity2
12.03.Cidara stock gains on JMP analyst's upbeat outlook3
CIDARA THERAPEUTICS Aktie jetzt für 0€ handeln
10.03.Cidara stock price target raised to $35 at H.C. Wainwright2
06.03.Cidara Therapeutics GAAP EPS of -$5.37 misses by $1.524
06.03.Cidara Therapeutics, Inc.: Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results136Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of efficacyClosed $105.0 million financing with new and existing investorsSignificantly...
► Artikel lesen
06.03.Cidara Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
06.03.Cidara Therapeutics, Inc. - 8-K, Current Report-
18.02.Cidara Therapeutics appoints new CFO amid flu drug trials2
18.02.Cidara Therapeutics ernennt neuen CFO2
18.02.Cidara Therapeutics appoints Frank Karbe as CFO4
18.02.Cidara Therapeutics, Inc.: Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer125 SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies...
► Artikel lesen
18.02.Cidara Therapeutics, Inc. - 8-K, Current Report-
13.01.Here's Why Cidara Therapeutics, Inc. (CDTX) Is Skyrocketing10
07.01.Cidara Therapeutics, Inc. - 8-K, Current Report9
23.12.24Cidara Therapeutics files to sell 7.04M shares of common stocks by selling shareholders15
04.12.24Cidara Therapeutics, Inc.: Cidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza161SAN DIEGO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies...
► Artikel lesen
Seite:  Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1